UroGen Pharma Ltd.
URGN
$9.87
-$0.27-2.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.25M | 24.57M | 25.20M | 21.85M | 18.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.25M | 24.57M | 25.20M | 21.85M | 18.78M |
| Cost of Revenue | 2.33M | 2.47M | 2.45M | 2.23M | 1.73M |
| Gross Profit | 17.92M | 22.09M | 22.75M | 19.62M | 17.05M |
| SG&A Expenses | 34.97M | 33.76M | 28.94M | 30.06M | 27.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.17M | 51.12M | 42.75M | 47.69M | 44.52M |
| Operating Income | -36.91M | -26.56M | -17.55M | -25.84M | -25.74M |
| Income Before Tax | -43.45M | -34.86M | -23.58M | -33.37M | -32.23M |
| Income Tax Expenses | 392.00K | 2.65M | 91.00K | 38.00K | 54.00K |
| Earnings from Continuing Operations | -43.84M | -37.51M | -23.67M | -33.40M | -32.29M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.84M | -37.51M | -23.67M | -33.40M | -32.29M |
| EBIT | -36.91M | -26.56M | -17.55M | -25.84M | -25.74M |
| EBITDA | -36.84M | -26.49M | -17.48M | -25.77M | -25.62M |
| EPS Basic | -0.92 | -0.80 | -0.55 | -0.91 | -0.87 |
| Normalized Basic EPS | -0.57 | -0.45 | -0.34 | -0.57 | -0.54 |
| EPS Diluted | -0.92 | -0.80 | -0.55 | -0.91 | -0.87 |
| Normalized Diluted EPS | -0.57 | -0.45 | -0.34 | -0.57 | -0.54 |
| Average Basic Shares Outstanding | 47.42M | 47.03M | 43.10M | 36.82M | 37.06M |
| Average Diluted Shares Outstanding | 47.42M | 47.03M | 43.10M | 36.82M | 37.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |